Hematology Frontier

At the recently held International Congress of Hematology, treatment advances in the field of Myeloproliferative Neoplasms (MPN) have garnered significant attention. As a classic subtype of MPN, Essential Thrombocythemia (ET) has seen no substantial breakthroughs in its treatment over the past two decades. In a Plenary Presentation, Professor Harry Gill of the University of Hong Kong's School of Clinical Medicine, on behalf of collaborators from 59 research centers worldwide, announced the top-line data from the Phase III SURPASS-ET clinical study. The study confirms that the novel long-acting interferon, Ropeginterferon alfa-2b (hereinafter referred to as Ropeginterferon), is comprehensively superior to the conventional drug anagrelide in both efficacy and safety as a second-line therapy, bringing new hope to patients with high-risk ET.

The 30th European Hematology Association (EHA) Annual Meeting 2025 was grandly held in Milan, Italy, gathering top experts from the global hematology community to discuss and share the latest research progress and cutting-edge technologies in the field. During the Plenary Session, Professor David Curtis from the Australasian Leukaemia and Lymphoma Group (ALLG), on behalf of his team, announced the first results of the ALLG BM12 CAST clinical trial. This Phase III randomized controlled trial, focusing on peripheral blood stem cell transplantation from matched sibling donors, provides powerful "practice-changing" evidence to solve the challenge of Graft-versus-Host Disease (GVHD) prophylaxis, a problem that has puzzled clinicians for nearly forty years, sparking significant interest and heated discussion among attendees.

The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in person, gathering top experts and cutting-edge research from the global hematology community. At this conference, a revolutionary study on the origin of Chronic Lymphocytic Leukemia (CLL) attracted widespread attention. A research team from Spain, using multi-omics single-cell sequencing technologies, revealed that CLL does not, as traditionally believed, originate from a single clone. Instead, in some patients, multiple independent minor clones with the biological characteristics of CLL exist, having emerged and begun to evolve decades before the disease is diagnosed. This discovery not only profoundly reshapes our understanding of CLL pathogenesis but also provides a completely new theoretical basis for future early diagnosis and intervention strategies.

The 2025 European Hematology Association (EHA) Annual Meeting was held in a hybrid format, both online and in-person, gathering top experts and scholars from the global hematology community. The conference focused on the deep integration of cutting-edge technology and clinical practice, with the application of Artificial Intelligence (AI) being one of the core topics. Professor Jakob Nikolas Kather from the Technische Universität Dresden, Germany, was invited to deliver a keynote speech titled "Artificial Intelligence in Hematology: Opportunities, Pitfalls, and How to Bring It into Clinical Practice." He systematically described the revolutionary changes in AI technology from its early explorations to the current era of large models. He particularly highlighted his team's pioneering research on empowering Tumor Board decision-making with AI Agents, charting a course for the future development of AI in hematologic oncology.

The 2025 European Hematology Association (EHA) Annual Meeting was recently held, bringing together top global experts in the field of hematologic malignancies to discuss the latest research findings and future directions. In the highly anticipated "Late-Breaking Abstract" session, Professor John Mascarenhas from the Icahn School of Medicine at Mount Sinai presented clinical study data on INCA33989, a novel, first-in-class monoclonal antibody specific to mutant calreticulin (CALR). The study results showed that INCA33989 demonstrated excellent safety and revolutionary therapeutic potential in previously treated patients with Essential Thrombocythemia (ET), with the potential to change the current treatment landscape

Editor's Note: With advancements in medicine, allogeneic hematopoietic cell transplantation (allo-HCT) has become a hope for a cure for many patients with high-risk hematologic malignancies. However, the high risks and…

Editor's Note: From June 12 to 15, 2025, the European Hematology Association (EHA) Annual Congress was held in Milan, Italy, bringing together top experts in the field of hematology from…

Editor's Note: At the 2025 European Hematology Association (EHA) Annual Congress, a dedicated guideline session was grandly held, bringing together top experts in the global hematology field. One of the…

Editor's Note: At the European Hematology Association (EHA) 2025 Annual Congress, the special session on Multiple Myeloma (MM) was filled to capacity. The core focus of the meeting was the…

Editor's Note: During the 2025 European Hematology Association (EHA) Annual Meeting, a session on the interpretation of the new Peripheral T-Cell Lymphoma (PTCL) guidelines drew significant attention. At this session,…